Compumedics Limited ( (AU:CMP) ) has shared an announcement.
Compumedics Limited reported a decline in revenue and profit for the half-year ended December 31, 2024, with revenue down 11% and a net loss of $1,114,000. Despite the financial downturn, the company achieved record new sales orders of $32.8 million, a 9% increase from the previous year, driven by significant growth in its sleep and neurology business and a 40% rise in SaaS/annuity sales orders.
More about Compumedics Limited
Compumedics Limited operates in the medical technology industry, focusing on the development and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood flow monitoring. The company provides products and services primarily in the areas of sleep and neurology, with a growing emphasis on software-as-a-service (SaaS) and annuity-based sales.
YTD Price Performance: 9.62%
Average Trading Volume: 56,148
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$54.78M
Learn more about CMP stock on TipRanks’ Stock Analysis page.